BioSpace News Archive

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced an update on patient enrollment for its on-going Phase 3 clinical studies of simufilam for the treatment of Alzheimer’s disease dementia.

OcuSciences, a medical device company developing ocular imagers to detect early disease by assessing retinal metabolic activity, today announced the publication of an Age-related Macular Degeneration (AMD) study in the Ophthalmic Surgery, Lasers and Imaging Retina journal.

Logomix, Inc., a Tokyo-based mammalian synthetic biology company developing artificial human cells for new therapeutics based on its pioneering

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce that it has received the results of an independent assessment of its proprietary gold nanorod nanoparticles from the National Cancer Institute’s Nanotechnology Characterization Laboratory

Ostial Corporation, a private medical technology company focused on addressing the clinical challenges of aorto-ostial interventions, announced the raise of $7M in growth funding led by Delos Capital with participation from AMED Ventures and other existing investors.

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its first NovaSeq X Plus system was recently delivered to the Broad Institute.

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced a portfolio reprioritization.

PDS Biotechnology Corporation announced that preclinical studies involving Infectimune™, PDS Biotech’s novel investigational immune activating platform, were published in the peer-reviewed journal, Viruses, demonstrating the technology’s ability to generate a broad immune response against viruses, including SARS-CoV-2 and multiple strains of influenza.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2022.

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX) today announced its financial results for the fourth quarter and year ended December 31, 2022, and provided an update on its clinical pipeline and other corporate developments.